drugset / Trial / NCT03204227

Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age

NCT03204227

RandomizedParallel-groupQuadruple-blindPrevention

Summary

A study of the study vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the safety of the study vaccine compares to licenced vaccine. Two hundred and twenty children are enrolled and randomly assigned into 2 groups (110 children/group), each of which receive 2 doses of study / control vaccine subcutaneously, at 28-34 days interval. Safety data included immediate reaction at the injection site and systemic reaction within 30 min of administration, solicited and unsolicited adverse events occurs from the 1st dose to 28-34 days after first dose and from the second dose to 28-34 days after 2nd dose. SAE (from start of first dose to 28-34 days after second dose).

Timeline

Start
2017-06-02
Primary completion
2017-08-12
Completion
2017-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject JECEVAX Vaccine 0.5 ml Subcutaneous
Comparator JEVAX-VABIOTECH-Vietnam Vaccine 0.5 ml Subcutaneous

Indications